Sinonasal malignancies: A population-based analysis of site-specific incidence and survival

Laryngoscope. 2015 Nov;125(11):2491-7. doi: 10.1002/lary.25465. Epub 2015 Jul 30.

Abstract

Objectives/hypothesis: Sinonasal malignancies vary in behavior according to histology and anatomical location. Incidence, survival, and optimal treatment for these lesions are thus uncertain in various cases. Our objective was to utilize a national population-based registry to identify the most common sinonasal histopathologies by anatomical site, and subsequently analyze the data by incidence trends, survival rates, patient demographics, and treatment modalities.

Study design: Retrospective analysis of the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry.

Methods: The SEER database was examined for patients diagnosed with sinonasal malignancies between 1973 and 2011. Data were stratified according to anatomical site, incidence, survival, histology, staging, and patient demographics. Therapy-based outcomes were analyzed for cases from 1983 to 2011.

Results: A total of 13,295 patients were identified, with an incidence of 0.83 per 100,000 people. Males comprised 58.6% of cases. Whites represented 81.5% of cases, while blacks comprised 8.7%. Squamous cell carcinoma was the most common histology (41.9%) across all sites of the sinonasal tract. The most common anatomical site of malignancy was the nasal cavity (45.7%), and least common was the frontal sinus (1.2%). For single sites, 5-year disease-specific survival (DSS) was highest for nasal cavity tumors (67.1%) and lowest for overlapping sinus malignancies (37.6%). The overall 5-year DSS for all sinonasal malignancies was 53.7%.

Conclusion: Sinonasal malignancies are rare entities with poor overall prognosis. By anatomical site, prognosis is best for nasal cavity cancers and worst for overlapping lesions.

Level of evidence: 4.

Keywords: SEER; Sinonasal tumor; demographic; disease-specific survival; incidence; sinonasal cancer; sinonasal malignancy; sinus cancer; site-specific survival; survival.

MeSH terms

  • Female
  • Humans
  • Male
  • Neoplasm Staging
  • Paranasal Sinus Neoplasms / epidemiology*
  • Paranasal Sinus Neoplasms / mortality
  • Paranasal Sinus Neoplasms / pathology
  • Prognosis
  • Registries
  • Retrospective Studies
  • SEER Program
  • United States / epidemiology